A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Sep 2017 Results of exploratory analysis assessing overall survival by using baseline platelet count from three studies (SHARP, AP, and RESORCE) presented at the 42nd European Society for Medical Oncology Congress
    • 21 Jan 2017 Results (n=828) from NCT00105443 and NCT00492752 trials assessing the correlation between time to progression (TTP) and overall survival, presented at the 2017 Gastrointestinal Cancers Symposium.
    • 11 Oct 2016 Results from SHARP and Asia Pacific trials assessing the association of overall survival with tumor growth rate (TGR) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top